摘要:
The present invention provides an SSAO inhibitor and an application thereof in preparing a drug for treating a disease related to SSAO. In particular, the present invention provides a compound shown in formula (IV) and a pharmaceutically acceptable salt thereof.
摘要:
The subject invention concerns novel compounds that are useful as ultrashort acting hypnotic barbiturates. Specifically exemplified are derivatives of barbituric and thiobarbituric acids. They are rapidly metabolized by blood and tissue enzymes to form polar metabolites with no hypnotic activity and which are rapidly eliminated.
摘要:
Provided is a preparation method for revaprazan hydrochloride, the method comprising: (1) the preparation of 4-hydroxyl-2-(4-fluoroaniline)-5,6-dimethylpyrimidine; (2) the preparation of 4-chloro-2-(4-fluoroaniline)-5,6-dimethylpyrimidine; (3) the preparation of revaprazan hydrochloride. The method has advantages such as simple operations, high product purity, good yield and suitability for industrial production.
摘要:
Compounds are provided for use with DPP-IV of the formula: Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
摘要:
A 2-halo-pyrimidine-4-carboxylic acid of formula: ##STR1## wherein X is a halogen atom, for example, 2-chloro-pyrimidine-4-carboxylic acid. A 2-substituted-pyrimidine-4-carboxylic acid derivative of formula: ##STR2## wherein R.sub.1 is a halogen atom, NH.sub.2 --, HO-- or a C.sub.1 -C.sub.4 alkoxy group and R.sub.2 is a C.sub.1 -C.sub.4 alkoxy group or a halogen atom with the proviso that, if R.sub.1 is a HO-- group, R.sub.2 is not a halogen atom and with the proviso that, if R.sub.2 is a halo group, R.sub.1 is not an amino group. A 2-substituted-pyrimidine-4-carboxylic acid derivative of formula III wherein R.sub.1 is a HO-- group and R.sub.2 is an ethoxy group.
摘要:
Provided is a preparation method for revaprazan hydrochloride, the method comprising: (1) the preparation of 4-hydroxyl-2-(4-fluoroaniline)-5,6-dimethylpyrimidine; (2) the preparation of 4-chloro-2-(4-fluoroaniline)-5,6-dimethylpyrimidine; (3) the preparation of revaprazan hydrochloride. The method has advantages such as simple operations, high product purity, good yield and suitability for industrial production.
摘要:
Cycloalkylcarbonylamino acid ester derivatives, which are raw material intermediates for a novel cycloalkane carboxamide derivative having an action that selectively inhibits cathepsin K, and a production process thereof, are provided.A cycloalkylcarbonylamino acid ester derivative represented by formula (I), or a pharmaceutically acceptable salt thereof: (wherein, R1 and R2 represent alkyl groups, alkenyl groups, alkynyl groups, aromatic hydrocarbon groups, heterocyclic groups, etc., R8 represents an alkyl group having 1 to 6 carbon atoms, and ring A represents a cyclic alkylidene group having 5, 6 or 7 carbon atoms).
摘要:
New pharmacologically active heterocyclic derivatives as muscarinic receptor blocking agents, useful for the treatment of gastrointestinal disorders, of the following formula ##STR1## wherein the substituents are defined hereinbelow.
摘要:
A 2-nitriamino-1,3-diazacyclohexane of the formula ##STR1## wherein R is hydrogen, alkyl of from one to six carbon atoms or alkanoyl of from one to seven carbon atoms, and R.sup.1 is hydrogen or alkyl of from one to six carbon atoms, useful as insecticides.
摘要:
Certain arylmethyl amines have been prepared wherein the "methyl" carbon is substituted with a polyfluoroalkyl radical. The compounds form acid addition salts, exist in resolvable stereoisomeric forms, and are useful for treating hypertension. Formulations for human and veterinary medicine are described, as well as methods of use.